Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 5.06 as of 2026-10-06T10:51:17.427Z.
Consensus retrieved: 2026-10-06T10:48:33.059Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T10:51:17.427Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dda5353817af794375b978a2faa289dfa66a026ad884c07a98b38d1ad02c68b2
Forward PE Ratio (5.06) = Dated Quote Price ($0.99) / Consensus Forward EPS ($0.19)
FORWARD PE RATIO
5.06
SECTOR MEDIAN · HEALTHCARE
19.88
median of 117 covered companies
CURRENT VS SECTOR MEDIAN
-74.55%
vs the sector median at left
Definitive Healthcare Corp.
Market Cap
$104.07M
Forward PE Ratio
5.06
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Definitive Healthcare Corp. (DH) | $104.07M | 5.06 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $100.37M | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.39M | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
5.1
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.19 | $0.19 – $0.20 | 5 | 5.1x |
| 2027-12-31 | $0.19 | $0.12 – $0.22 | 5 | 5.3x |
| 2028-12-31 | $0.18 | $0.18 – $0.19 | 1 | 5.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
